Abbott Laboratories (NYSE:ABT – Get Rating) will post its quarterly earnings results on Wednesday, January 25th.
Abbott Laboratories Stock Performance
Abbott Laboratories stock opened at $114.01 on Tuesday. The company has a current ratio of 1.86, a quick ratio of 1.43 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average of $108.56 and a 200-day moving average of $105.76. The firm has a market cap of $198.78 billion, a P/E ratio of 25.74, a P/E/G ratio of 5.05 and a beta of 0.69. Abbott Laboratories has a 1-year low of $93.25 and a 1-year high of $130.93.
Abbott Laboratories Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 15th. Investors of record on Friday, January 13th will be paid a $0.51 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.47. This represents a $2.04 dividend on an annualized basis and a yield of 1.79%. The ex-dividend date of this dividend is Thursday, January 12th. Abbott Laboratories’s dividend payout ratio is presently 46.05%.
Wall Street Analyst Weigh In
Insider Activity at Abbott Laboratories
In related news, Director Daniel J. Starks sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 27th. The shares were sold at an average price of $97.46, for a total transaction of $4,873,000.00. Following the completion of the sale, the director now owns 6,873,500 shares of the company’s stock, valued at $669,891,310. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Daniel J. Starks sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 27th. The shares were sold at an average price of $97.46, for a total transaction of $4,873,000.00. Following the completion of the sale, the director now owns 6,873,500 shares of the company’s stock, valued at $669,891,310. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP John F. Ginascol sold 11,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $112.32, for a total transaction of $1,235,520.00. Following the sale, the executive vice president now directly owns 111,912 shares of the company’s stock, valued at approximately $12,569,955.84. The disclosure for this sale can be found here. 0.52% of the stock is owned by insiders.
Institutional Investors Weigh In On Abbott Laboratories
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Worth Asset Management LLC purchased a new stake in Abbott Laboratories in the first quarter worth approximately $108,000. Fairfield Bush & CO. purchased a new stake in Abbott Laboratories in the first quarter worth approximately $131,000. Global Wealth Management Investment Advisory Inc. boosted its holdings in Abbott Laboratories by 16.5% in the first quarter. Global Wealth Management Investment Advisory Inc. now owns 1,249 shares of the healthcare product maker’s stock worth $148,000 after purchasing an additional 177 shares during the last quarter. BCK Partners Inc. purchased a new stake in Abbott Laboratories in the first quarter worth approximately $220,000. Finally, Eudaimonia Advisors LLC purchased a new position in shares of Abbott Laboratories during the 1st quarter worth $240,000. Hedge funds and other institutional investors own 72.93% of the company’s stock.
Abbott Laboratories Company Profile
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products.
Further Reading
- Get a free copy of the StockNews.com research report on Abbott Laboratories (ABT)
- 3 Late January Earnings Plays With Pop Potential
- Low-Priced Stocks Still Paying Dividends
- Why is the Chipotle Stock Price Surging This Week?
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.